gip/glp-1 agonist GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica GLP-1 Agonists for Addiction

References 1 FDA Label Egrifta (tesamorelin)Prescribing information for tesamorelin, FDA-approved only for reduction of excess abdominal fat in HIV-associated lipodystrophy

It has been demonstrated that NRH increases NAD + more rapidly and robustly than NR or NMN

The right choice depends on your goal

T.RomeroL.et al (2014)

Given existing evidence, triple combination therapy can be expected to provide additional cardiorenal protection, although further randomized controlled trials are needed to determine whether triple combination therapy actually has additive or synergetic effects compared with mono or dual therapy

Stay Hydrated: Hydration is key to supporting the functions of collagen and glutathione in the body